satraplatin news from FierceBiotech
NewsReport: Wilex, GPC nearing merger pact
Two German biotech companies which share a very big investor are preparing to merge, according to a prominent German newspaper. Wilex and GPC Biotech, both involved in developing new cancer Read more...
Struggling GPC looking for merger or acquisition
Wanted: Private drug developer interested in partnering with struggling biotech specializing in cancer therapies. GPC Biotech essentially posted that message when its CEO announced that he is Read more...
GPC Biotech reports Q3 results, layoffs
GPC Biotech is regrouping after last week's announcement Read more...
GPC shares crater on Phase III cancer failure
Germany's GPC Biotech saw its already battered stock price crater this morning after announcing that its experimental prostate cancer drug, satraplatin, failed to help patients live longer in a Read more...
FDA delay forces cutbacks at GPC Biotech
Struggling to overcome FDA hurdles for its cancer drug satraplatin, Germany's GPC Biotech says it will slash its staff by 15 Read more...
SPOTLIGHT: GPC hit by high R&D costs
Germany's GPC Biotech announced wider losses as a result of the expense of developing its prostate cancer therapy Satraplatin. A recent delay in gaining FDA approval of the drug sent GPC shares Read more...
Industry exec says FDA approval process too strict
Citing the recent decision by GPC Biotech to withdraw its application for satraplatin, Pharmacyclics Read more...
GPC yanks FDA application for satraplatin
Stymied by FDA regulators, GPC Biotech has pulled its application for satraplatin, an Read more...
GPC cancer drug voted down by FDA committee
An FDA expert committee has dealt a blow to GPC Biotech, concluding unanimously that regulators should wait for survival data before approving its prostate cancer drug Orplatna (satraplatin). The Read more...
| Press ReleasesPRESS RELEASE: GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial • Overall survival results do not achieve statistical significance • GPC Biotech Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends